The American Hospital Association and other plaintiffs asked a federal court Nov. 16 to block HRSA’s 340B rebate program before it takes effect Jan. 1, according to a reply brief filed in the U.S. District Court for the District of Maine.
Here are six things to know:
- The filing replies to oppositions from HHS and drugmaker intervenors to the plaintiffs’ motion for a preliminary injunction in American Hospital Association v. Kennedy. The plaintiffs ask the court to preliminarily enjoin the rebate program and any approvals of drug companies’ applications to participate.
- The plaintiffs argue HHS did not heed the court’s earlier instruction to “fortify” the program after a December 2025 ruling and that its revised program fails the Administrative Procedure Act’s reasoned decision-making standard.
- The brief says HRSA’s only calculation of the program’s costs is $537 million a year for covered entities to submit claims data, a figure based on an estimate that submissions will take five hours a week. The plaintiffs say neither HHS nor the intervenors explain where the estimate comes from and that record evidence shows far more labor is needed.
- The plaintiffs say HRSA excluded financing “float” costs and relied on an outdated version of an IQVIA study. The updated study calculated $53.7 million in annual interest costs for just 10 drugs in the program, according to the brief.
- On benefits, the plaintiffs say HHS “says almost nothing” about what the program would deliver and does not quantify those benefits, so the court cannot judge whether they bear a rational relationship to costs. They argue the program would impose hundreds of millions of dollars in costs that would lead 340B hospitals to cut services.
- The brief challenges drugmakers’ claims of harm without the program, noting AbbVie projects $35.8 million in duplicate discount losses in 2027 but bought back $1.1 billion of its stock in the first nine months of 2026.